Radius Health, Inc. (NASDAQ: RDUS) was founded in 2003 and is headquartered in Waltham, Massachusetts, USA, with 398 full-time employees. It is a company specializing in bone research and development. Biopharmaceutical company with innovative treatments for porosity and other serious endocrine-induced diseases.
Radius Health’s main products include:
- Abaloparatide-SC-an injectable intraperitoneal injection preparation (Abaloparatide injection) for the treatment of postmenopausal osteoporosis patients, has completed phase III clinical trials.
- Abaloparatide-TD——Abaloparatide patch.
- RAD1901, a selective estrogen receptor lowering regulator/degradant, is currently in a phase I clinical trial for the treatment of metastatic breast cancer; at the same time, it is in a phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms.
- RAD140-a non-steroidal selective androgen receptor modulator for the treatment of breast cancer.
Fangyuan Health Company has already cooperated with 3M Company , Ipsen Pharma SAS ( Ipsen Pharma SAS ), Eisai Co. Ltd (Eisai Pharmaceutical), Lonza Group Ltd (Lonza Group), Novartis Pharmaceuticals and Takeda Pharmaceutical Company Limited (Takeda Pharmaceutical) has signed a cooperation or license agreement, and signed a research and development agreement with Nordic Bioscience Clinical Development VII A/S (Nordic Bioscience Clinical Development VII A/S).